51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

  
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01309997
(ClinicalTrials.gov)
March 20111/3/2011Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseA Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell TransplantationGraft Versus Host Disease;Systemic SclerodermaDrug: imatinib mesylate;Biological: rituximabLee, StephanieNational Cancer Institute (NCI)Completed2 YearsN/AAll72Phase 2United States
2NCT00573326
(ClinicalTrials.gov)
February 200913/12/2007Low-Dose Oral Imatinib for Scleroderma Pulmonary InvolvementLow-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot StudySystemic SclerosisDrug: ImatinibAzienda Ospedaliera Universitaria PoliclinicoUniversità Politecnica delle MarcheRecruiting18 Years80 YearsBoth30Phase 2Italy
3EUCTR2007-004669-17-IT
(EUCTR)
17/12/200816/06/2008A multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis - NDA multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis - ND sistemic sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10018124;Term: Generalized scleroderma
Trade Name: GLIVEC
INN or Proposed INN: IMATINIB MESILATO
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
27United Kingdom;Italy
4EUCTR2007-004669-17-DE
(EUCTR)
10/07/200813/03/2008A multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosisA multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis systemic sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10042953;Term: Systemic sclerosis
Trade Name: Glivec 100 mg Filmtabletten
Product Name: Glivec
Product Code: STI571
INN or Proposed INN: imatinib
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
27Germany;Italy;United Kingdom
5NCT01545427
(ClinicalTrials.gov)
April 20081/3/2012Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaA Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaSclerodermaDrug: Imatinib mesylate;Other: PlaceboLawson Health Research InstituteNovartis PharmaceuticalsTerminated18 YearsN/ABoth10Phase 2Canada
6EUCTR2007-004669-17-GB
(EUCTR)
15/02/200816/10/2007A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosisA multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis Skin fibrosis in systemic sclerosis patients
MedDRA version: 9.1;Level: LLT;Classification code 10042953;Term: Systemic sclerosis
Trade Name: Glivec
Product Name: Glivec
Product Code: STI571
INN or Proposed INN: imatinib
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
27United Kingdom;Italy
7NCT00613171
(ClinicalTrials.gov)
January 2, 200825/1/2008Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic SclerosisA Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic SclerosisSystemic Sclerosis, SclerodermaDrug: STI571Novartis PharmaceuticalsNULLCompleted18 YearsN/AAll27Phase 2United States;Germany;Italy;Switzerland;United Kingdom
8NCT00479934
(ClinicalTrials.gov)
December 200729/5/2007Efficacy and Safety of Imatinib in SclerodermaPhase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.Scleroderma, Localized;Scleroderma, SystemicDrug: imatinib mesylateUniversity Hospital, BordeauxMinistry of Health, France;NovartisCompleted18 YearsN/ABoth28Phase 2France
9EUCTR2007-005322-68-IT
(EUCTR)
30/10/200704/10/2007Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study - Imatinib in sclerodermaLow-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study - Imatinib in scleroderma Systemic Sclerosis
MedDRA version: 6.1;Level: PT;Classification code 10042953
Trade Name: GLIVEC
INN or Proposed INN: Imatinib
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Italy
10EUCTR2007-001508-19-IT
(EUCTR)
06/09/200729/07/2008TRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE - NDTRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE - ND GVH CRONICA ESTESA
MedDRA version: 9.1;Level: LLT;Classification code 10018651;Term: Graft versus host disease
Trade Name: GLIVEC
INN or Proposed INN: Imatinib
AZIENDA OSPEDALIERA S. CARLONULLNot RecruitingFemale: yes
Male: yes
Italy
11EUCTR2006-007091-15-NL
(EUCTR)
03/09/200702/04/2007Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosisGlivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosis systemic sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10039710;Term: Scleroderma
Product Name: GlivecErasmusMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Netherlands
12NCT00555581
(ClinicalTrials.gov)
August 20077/11/2007Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisPhase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisSystemic SclerosisDrug: Imatinib MesylateHospital for Special Surgery, New YorkNovartis PharmaceuticalsCompleted18 YearsN/AAll30Phase 2United States
13NCT00512902
(ClinicalTrials.gov)
August 20076/8/2007A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic SclerosisPilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic SclerosisAlveolitis;Systemic SclerosisDrug: ImatinibUniversity of California, Los AngelesNovartis PharmaceuticalsCompleted18 YearsN/AAll20Phase 1/Phase 2United States
14NCT00506831
(ClinicalTrials.gov)
July 200724/7/2007Imatinib in Systemic SclerosisA Pilot Study of Imatinib in the Treatment of Refractory Systemic SclerosisScleroderma, SystemicDrug: Imatinib mesylateStanford UniversityNULLCompleted18 Years80 YearsAll9Phase 1/Phase 2United States